PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

FDA approves Axsome first rapid-acting antidepressant

New York-based biopharma Axsome Therapeutics announced last week that the FDA had approved Auvelity, its oral n-methyl d-aspartate (NDMA) receptor drug developed to treat the major depressive disorder in adults.

Auvelity is the first and only NDMA receptor antagonist approved for the disorder, and Axsome says it sets itself apart from other antidepressants on the market by acting quicker than most.

“In clinical trials, Auvelity has demonstrated rapid and statistically significant improvement in depressive symptoms as early as Week 1, and increased rates of remission at Week 2 compared with placebo,” said Ian V. Iosifescu, MD, professor of psychiatry at the New York University School of Medicine.

Iosifescu also went on to explain that because the drug “targets glutamatergic neurotransmission, [Auvelity] provides clinicians with a long sought after new mechanistic approach which may benefit the millions of patients living with this serious condition.“

The FDA initially granted Breakthrough Designation for the drug in March of 2019. Based on results from the Gemini placebo-controlled study, which included more than 1,100 patients with depression.

Axsome anticipates Auvelity to be commercially available in the U.S. in the fourth quarter of 2022.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026